Australia's most trusted
source of pharma news
Tuesday, 08 July 2025
Posted 8 July 2025 AM
A mega licensing deal is in the works for a next-gen immunotherapy, worth up to $23 billion (US$15 billion).
AstraZeneca is in talks to license ivonescimab, a first-in-class, humanised tetravalent bispecific antibody targeting PD-1 and VEGF-A simultaneously, from Summit Therapeutics, according to Bloomberg.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.